Navigation Links
Personalized Medicine - A Global Market Overview
Date:8/16/2012

NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Personalized Medicine - A Global Market Overview

http://www.reportlinker.com/p0955290/Personalized-Medicine---A-Global-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

`Personalized Medicine can mean a lot of things to a lot of people. For some, it may relate to doctors having knowledge about their case history and the treatment received, which is a morale boosting factor, since everybody wants caregivers who can comprehend an individual's problems. The day is not very far when this level of personal or individual understanding between a patient and a doctor would be much deeper than hitherto anticipated. The coming decade is expected to witness an increase in the use of companion diagnostics and personalized medicines, with pricing incentives and efficiency improvement propelling the market. Current market leaders with diagnostic divisions focusing on biomarker identification would be at an advantage.

This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.

The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.

This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology. The report covers the brief business profiles of 56 key global players and 77 major players across the United States – 45; Europe – 24; and Rest of World – 8. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.

TABLE OF CONTENTS:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION1.1 Product Outline1.1.1 Personalized Medicine's Influence on Large Scale Studies1.1.2 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine1.1.3 Ramifications of Personalized Medicine for Healthcare Systems1.1.3.1 Pharmaceutical Industry1.1.3.2 Diagnostics Industry1.1.3.3 Insurers1.1.3.4 Physicians1.1.3.5 Government Agencies1.1.3.6 Patients1.1.4 Analysis of Personalized Medicine by Segment1.1.4.1 Targeted Biologics1.1.4.1.1 Overview1.1.4.1.2 Targeted Biologics for Breast Cancer: An Illustration1.1.4.2 Proteomics & Genomics1.1.4.2.1 Proteomics1.1.4.2.1.1 A Complex Problem1.1.4.2.1.2 Post-Translational Modifications1.1.4.2.1.3 Phosphorylation1.1.4.2.1.4 Ubiquitination1.1.4.2.1.5 Other Modifications1.1.4.2.2 Genomics1.1.4.2.2.1 Pharmacogenomics1.1.4.3 Genetically Modified (GM) Products1.1.4.3.1 The Genetic Engineering Process1.1.4.3.1.1 Applications of Genetic Engineering1.1.4.4 Wellness & Disease Management1.1.4.4.1 Wellness Defined1.1.4.4.2 Disease Management Defined1.1.4.5 Molecular Diagnostic Technologies1.1.4.5.1 DNA Sequencing1.1.4.5.2 Biochips and Microarrays1.1.4.5.3 Cytogenetics1.1.4.5.3.1 Personalized Medicine Based on Molecular Cytogenetics1.1.4.5.3.2 Personalized Medicine Based on Cytomics1.1.4.5.4 Single Nucleotide Polymorphism (SNP) Genotyping1.1.4.5.4.1 Applications of SNPs Pertinent to Personalized Medicine1.1.4.5.5 Haplotyping1.1.4.5.6 Application of Proteomics In Molecular Diagnosis1.1.4.5.7 Gene Expression Profiling1.1.4.5.8 Personalized Medicine and Molecular Imaging1.1.4.5.9 Diagnostics Based On Glycomics1.1.4.5.10 Combining Diagnostics and Therapeutics1.1.4.5.11 Point-Of-Care (POC) Diagnosis1.1.4.5.12 Genetic Testing For Disease Predisposition1.1.5 Analysis of Personalized Medicine by Technology1.1.5.1 Pharmacogenomics1.1.5.1.1 Drug Metabolism1.1.5.1.2 Applications1.1.5.2 Point-of-Care Testing1.1.5.2.1 Tests that are Most Apt for Specific Scenarios1.1.5.2.2 Advantages1.1.5.3 Stem Cell Therapy1.1.5.3.1 Treatment with Stem Cells1.1.5.3.2 Current Therapies1.1.5.3.3 Future Treatments1.1.5.4 Pharmacoproteomics1.1.5.5 Pharmacogenetics1.1.5.5.1 Prediction of Drug-Drug Interactions1.1.5.5.2 Integration of Pharmacogenetics with the Healthcare System1.1.5.5.3 Pharmacogenetic Tests1.1.5.6 Other Personalized Medicine Technologies1.1.5.6.1 Biochips1.1.5.6.2 Genetic Screening1.1.5.6.3 Metabolomics1.1.5.6.4 Molecular Diagnostics1.1.5.6.5 Pharmacodynamics1.1.5.6.6 Pharmacokinetics1.1.5.6.7 SNP Genotyping1.1.6 The Rationale Behind Personalized Medicine: "One Size no Longer Fits All"1.1.7 The Human Genome: What is It?

2. KEY MARKET TRENDS

Combating Melanoma and Lung Cancer Facilitated Using Novel Personalized Drugs

Personalized Medicine for Heart Patients Promised by University of Florida Academic Health Center

Personalized Medicine Integrated with Biosensors

Decade-Long Penn Medicine Study of HIV Patients Demonstrates Safety of Genetically Modified T Cell Therapy

Managing Infectious Diseases Using Point-of-Care Personalized Medicine Molecular Diagnostic Technologies

Introduction

Personalized Medicine and Infectious Diseases: An Unlikely Combination?

Universities to be Commended for Bringing Personalized Medicine to Patient Care

Nuclear Imaging Market to be Boosted through a Trend towards Personalized Medicine

Personalized Medicine for Lung Cancer Makes Progress

Micro RNA Denotes Response to Chemoprevention

Shorter Survival Predicted from RRM

Differentiating Tumor Types through Epigenetic Clues

Pharmaceutical and Diagnostic Company Business Models being Challenged by Personalized Medicine

Personalized Medicine and Pharmacogenomics: Single Nucleotide Polymorphisms' (SNPs) Role in Drug Therapy

Personalization of Medicine and the Role of SNPs

The Arrival of Pharmacogenetics and Illustrations of SNPs in Personalized Medicine

Personalized Medicine's Drawbacks in the Context of Genetic Discrimination

Personalized Medicine's Promise of Offering the Future Now

The Course of Advancements in Cancers

Live Healthy to Make a Difference

Personalized Medicine in Cancer Hits a Roadblock

Implications of Personalized Medicine for Pharmaceutical Manufacturers and Drug Development

Implications of Personalized Medicine

What Should Drug Developers Do

Is Drug Safety Capable of Being Improved through Personalized Medicine?

Personalized Medicine: A SWOT Analysis for Pharmacists

Strengths

Weaknesses

Opportunities

Threats

Genetic Testing for Identifying and Treating Specific Disorders

The Scientific and Commercial Facets of Personalized Medicine

Prevention and Treatment of Diabetes with Personalized Medicine

Medical Informatics and Personalized Medicine

Personalized Medicine for Treating Asthma

Personalized Medicine and Systems Engineering

The Evolving Role of CROs in Personalized Medicine

Personalized Medicine Being Guided by Stem Cell Therapies

Device Manufacturers Offered Better Prospects from the Trend Towards Personalized Medicine

3. KEY GLOBAL PLAYERSAbbott Laboratories, Inc.Affymetrix, Inc.Agendia B.V.Agilent Technologies, Inc.Amgen, Inc.Astellas Pharma Inc.AstraZeneca PlcBaxter International Inc.Bayer AGBayer Healthcare AGBeckman Coulter, Inc.BG Medicine, Inc.Biocartis NVBiocartis SABiogen IdecbioMérieux SABoehringer Ingelheim GmbHBristol-Myers Squibb CompanyCaliper Life Sciences, Inc.Celera CorporationCelgene CorporationCytolon AGDaiichi Sankyo Company LimitedDako A/SDecode GeneticsEli Lilly and CompanyEvotec AGGE Healthcare Ltd.Gene LogicGenelex CorporationGenentech, Inc.Gen-Probe IncorporatedGenzyme CorporationGlaxoSmithKline, PLCHistoRx, Inc.Ingenuity Systems, Inc.Johnson & JohnsonLaboratory Corporation of AmericaLife Technologies CorporationMerck KGaAMillennium LaboratoriesMitsubishi Tanabe Pharma CorporationMyriad Genetics, Inc.Novartis AGPerkinElmer, Inc.Pfizer IncRoche Diagnostics CorporationRoche Holding Ltd.SanofiSiemens AGSiemens Healthcare Diagnostics Inc.Sigma-Aldrich CorporationTakeda Pharmaceutical Company LimitedTeva Pharmaceutical Industries Ltd.The European Personalized Medicine Association (EPEMED)Thermo Fisher Scientific Inc

4. KEY BUSINESS TRENDS

Lilly Partners with PrimeraDX for Novel Personalized Therapeutics

Sanofi Joins with Joslin Diabetes Centre to Develop New Drugs

New Personalized Medicine Centre to be opened by PerkinElmer

Roche Signs Strategic Pact with Med Fusion

Agendia Introduces a New 18-Gene Expression Signature

Affymetrix Enters Research Collaboration with MGH

Affymetrix Signs Research Contract with Leica

Millennium Labs Launches Innovative Pharmacogenetic Test

Genedata Expressionist Opted for by Takeda

Boehringer Ingelheim and Healthrageous in an Agreement

Merck KGaA and MDxHealth Form Collaboration

FDA Approves Colorectal Cancer Companion Diagnostic from Qiagen

KineMed Collaborates with GSK for Biomarker Discovery

bioTheraputics Expands PRÉCIS Biomarker Profiles

Quest Introduces New Molecular Test Panel

Biocartis Collaborates with Philips and Wellcome Trust

A Triangular Agreement Signed between Immunexpress, Debiopharm, and Biocartis

Lab21 Sings Pact with Major Pharma Companies to Develop Companion Diagnostic Assay

Clarient Acquires IP Rights for Developing ALK Biomarker Genetic Tests from Insight Genetics

Exosome Signs Agreement with Life Technologies to Use Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR

New Saliva Test for Personalized Medicine Launched by Millennium

NextGen Commercializes Assay for New Diagnostics Biomarkers in Brain Disorders

Sanofi Collaborates with Joslin Diabetes Center

Perjeta™ (Pertuzumab) for People with HER2-Positive Metastatic Breast Cancer Granted FDA Approval

Software Re-enlisted by Roche for Personalized Medicine Research

Teva All Set to Enter Personalized Medicine Field

Personalized Medicine Test for ADHD Launched by AssureRx Health

XALKORI® Launched in Canada by Pfizer

Abbott Acquires License for Novel Biomarkers from Stanford

GE Bags SeqWright

PerkinElmer Unveils HER2Sense for Breast Cancer Research

Celgene Files FDA Application for Multiple Myeloma Drug

Takeda and Metabolon in a Partnership

Abbott Acquires Biomarker Licenses

Biomed Analytics Platform Tested by IBM in Association with Italian Institute

Abbott Joins Hands with Merck to Develop Companion Diagnostic Test

Chronix Biomedical Inaugurates State-of-the-Art Mass Sequencing Laboratory for Personal Biomarkers

Personalized Medicine with New Analytics Platform Aimed by IBM

Personalized Medicine Offered by IBM Genomic Analytics Platform

Clinical Genomics Centre Launched in USA by Lab21 and ITOR

GlaxoSmithKline and Epistem in an Agreement

First Personalized Medicine Diagnostics Deals Signed by Siemens

Online Personalized Medicine Portal Launched by Cepmed

Dako Partners with Amgen to Develop Companion Diagnostic Test for Investigational Cancer Therapy

Personalized Medicine Partnership of Florida is to be Created

China's SFDA Approves First Microarray Instrument GCS 3000Dx v.2

Health Canada Approves First and Only Personalized Treatment for Deadliest Form of Skin Cancer

Partnership with Siemens, ViiV, Tocagen on new Personalized Medicine Tests

New Personalized Medicine Institute Launched by Moffitt Cancer Centre

Roche Bags EU Approval for Zelboraf

Amgen and Dako in an Alliance for Developing New Diagnostic Test for Cancer Therapy

Siemens Enters Personalized Medicine Field

Ventana Medical and Bayer Joins Forces to Develop Companion Diagnostic Test

AssureRx Launches GeneSightRx 1.8

bioTheranostics Unveils Precision Medicine Biomarkers

Genzyme Partners with Veracyte to Offer Personalized Solution for Thyroid Patients

Identification of DNA Variants for Personalized Medicine Research by Ingenuity

Genzyme and Veracyte in an Agreement

OvaGene Joins Forces with Moffitt Cancer Centre to Develop and Commercialize Proprietary microRNA Assays

Abbott Expands Agreement with GSK for Development of a Companion Diagnostic Test

Expansion of Personalized Medicine Pact by GSK and ABT for new Cancer Diagnostic

GlaxoSmithKline and Abbott in Agreement to Expand Personalized Medicine for Cancer Diagnostic

Siemens and Illumina in a Partnership

Genetically Modified Human Cell Lines for Breast Cancer Research from Sigma® Life Science

Pfizer's Xalkori and Abbott Demonstrate a Bright Scope in Personalized Medicine, Companion Diagnostics

GNS Healthcare Collaborates with Bristol-Myers Squibb

Coriell and IBM: Together Advancing Personalized Medicine

MDxHealth Expands Agreement with Merck for use of MGMT Assay in Brain Cancer Clinical Trials

Joint Development of Biomarkers in Oncology by Roche and Evotec

Ipsogen S.A Offered to make Acquisition with QIAGEN

Innovative COX-2 Probe Launched by Caliper Life Sciences

Caliper and Catholic Health Initiatives form Oncology Research Collaboration

Novel Patient-Specific Drug Targets Identified by GNS Healthcare and Biogen

Daiichi Sankyo Takes Over Plexxikon

Collaboration between Ipsen SA and BioMerieux SA in Personalized Medicine

Oncology Disease Model Cell Lines Launched by Sigma® Life Science

AstraZeneca and HealthCore Form Collaboration

Minority Stake in Alacris Theranostics acquired by QIAGEN

GenomeQuest Partners with Ingenuity for Next-Generation Sequencing

GenomeQuest and Ingenuity Systems Form Partnership

Veridex and Massachusetts General Hospital Form Collaboration

Development of Personalized Medicine Further Accelerated with the Partnership between Dako and Quintiles

First Pharmacogenomics Test Launched by Luminex Corp. for Personalized Medicine

Integration of Software between Ingenuity Systems and TransMed to Support Personalized Medicine Research

Advancement of Personalized Medicine with the Launch of New Multiplex Tissue Biomarker Technology

Personalized Medicine Brought to Market by Iris Biotechnologies (OTCBB: IRSB)

5. GLOBAL MARKET OVERVIEW5.1 Market Overview by Product Type5.2 Market Overview by Technology5.3 Personalized Medicine Product Type Overview by Global Region5.3.1 Targeted Biologics5.3.2 Proteomics & Genomics5.3.3 Genetically Modified (GM) Products5.3.4 Wellness & Disease Management5.3.5 Other Molecular Diagnostic Products5.3.6 Self/Other Diagnostics5.4 Personalized Medicine Technology Overview by Global Region5.4.1 Pharmacogenomics5.4.2 Point-of-Care Testing5.4.3 Stem Cell Therapy5.4.4 Pharmacoproteomics5.4.5 Pharmacogenetics5.4.6 Other Personalized Medicine Technologies

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES

1.1 Market Overview by Product Type

1.2 Market Overview by Technology

1.3 Major Market Players

Abbott Laboratories, Inc.

Abbott Molecular Inc

Affymetrix, Inc.

Agilent Technologies, Inc.

Amgen, Inc.

Asuragen, Inc.

Baxter International Inc.

Beckman Coulter Genomics Inc.

Beckman Coulter, Inc.

BG Medicine, Inc.

Biogen Idec

Bristol-Myers Squibb Company

Caliper Life Sciences, Inc.

Celera Corporation

Celgene Corporation

Celldex Therapeutics

Cepheid

DNA Direct, Inc.

Eli Lilly and Company

Exact Sciences Corp.

Exagen Diagnostics, Inc.

Gene Logic

Genelex Corporation

Genentech, Inc.

Genomic Health Inc

Gen-Probe Incorporated

Genzyme Corporation

HistoRx, Inc.

Hologic Inc

Illumina, Inc.

Ingenuity Systems, Inc.

Johnson & Johnson

Laboratory Corporation of America (LABCORP)

Life Technologies Corporation

Luminex Corporation

Millennium Laboratories

Myriad Genetics, Inc.

PerkinElmer, Inc.

Pfizer Inc

Promega Corporation

Roche Diagnostics Corporation

Siemens Healthcare Diagnostics Inc.

Sigma-Aldrich Corporation

Thermo Fisher Scientific Inc

Ventana Medical Systems, Inc.

2. EUROPE2.1 Market Overview by Product Type2.2 Market Overview by Technology2.3 Major Market PlayersAgendia B.V. (The Netherlands)AstraZeneca PLC (United Kingdom)Bayer AG (Germany)Bayer Healthcare AG (Germany)Bayer Healthcare Pharmaceuticals (Germany)Biocartis NV (Belgium)Biocartis SA (Switzerland)bioMérieux SA (France)Boehringer Ingelheim GmbH (Germany)Cytolon AG (Germany)Dako A/S (Denmark)Decode Genetics (Iceland)Epistem Holdings PLC (United Kingdom)Evotec AG (Germany)GE Healthcare Ltd. (United Kingdom)GlaxoSmithKline, PLC (United Kingdom)Merck KGaA (Germany)Novartis AG (Switzerland)Qiagen N.V. (The Netherlands)Roche Holding Ltd. (Switzerland)Sanofi (France)Siemens AG (Germany)Siemens Healthcare (Germany)The European Personalised Medicine Association (EPEMED) (Luxembourg)

3. REST OF WORLD

3.1 Market Overview by Product Type

3.2 Market Overview by Technology

3.3 Major Market Players

Astellas Pharma Inc. (Japan)

Cepmed (Canada)

Daiichi Sankyo Company Limited (Japan)

DNA Genotek Inc. (Canada)

Mitsubishi Tanabe Pharma Corporation (Japan)

Rosetta Genomics Ltd. (Israel)

Teva Pharmaceutical Industries Ltd. (Israel)

Takeda Pharmaceutical Company Limited (Japan)

PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA

1.1 Canada

1.2 United States

2. EUROPE2.1 Austria2.2 Belgium2.3 Denmark2.4 France2.5 Germany2.6 Iceland2.7 Ireland2.8 Italy2.9 Luxembourg2.10 Spain2.11 Switzerland2.12 The Netherlands2.13 United Kingdom

3. ASIA-PACIFIC

3.1 Australia

3.2 China

3.3 Hong Kong

3.4 Japan

3.5 New Zealand

3.6 South Korea

3.7 Taiwan

4. REST OF WORLD4.1 Israel

5. RESEARCH & EDUCATIONAL INSTITUTIONS

PART D: ANNEXURE1. RESEARCH METHODOLOGY2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVEChart 1: Global Personalized Medicine Market Analysis (2008-2018) in USD MillionChart 2: Global Personalized Medicine Market Analysis (2008-2018) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD MillionChart 3: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other DiagnosticsChart 4: Global Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD MillionChart 5: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other TechnologiesChart 6: Global Market Analysis of Targeted Biologics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD MillionChart 7: Glance at 2008, 2013 and 2018 Global Market Share (%) of Targeted Biologics in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 8: Global Market Analysis of Proteomics & Genomics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD MillionChart 9: Glance at 2008, 2013 and 2018 Global Market Share (%) of Proteomics & Genomics in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 10: Global Market Analysis of Genetically Modified (GM) Products in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD MillionChart 11: Glance at 2008, 2013 and 2018 Global Market Share (%) of Genetically Modified (GM) Products in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 12: Global Market Analysis of Wellness & Disease Management in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD MillionChart 13: Glance at 2008, 2013 and 2018 Global Market Share (%) of Wellness & Disease Management in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 14: Global Market Analysis of Other Molecular Diagnostics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD MillionChart 15: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Molecular Diagnostics in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 16: Global Market Analysis of Self/Other Diagnostics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD MillionChart 17: Glance at 2008, 2013 and 2018 Global Market Share (%) of Self/Other Diagnostics in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 18: Global Market Analysis of Pharmacogenomics in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD MillionChart 19: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenomics in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 20: Global Market Analysis of Point-of-Care Testing in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD MillionChart 21: Glance at 2008, 2013 and 2018 Global Market Share (%) of Point-of-Care Testing in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 22: Global Market Analysis of Stem Cell Therapy in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD MillionChart 23: Glance at 2008, 2013 and 2018 Global Market Share (%) of Stem Cell Therapy in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 24: Global Market Analysis of Pharmacoproteomics in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD MillionChart 25: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacoproteomics in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 26: Global Market Analysis of Pharmacogenetics in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD MillionChart 27: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenetics in Personalized Medicine by Geographic Region – United States, Europe and Rest of WorldChart 28: Global Market Analysis of Other Personalized Medicine Technologies (2008-2018) Geographic Region – United States, Europe and Rest of World in USD MillionChart 29: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Personalized Medicine Technologies by Geographic Region – United States, Europe and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 30: Global Personalized Medicine Market Analysis (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 31: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Geographic Region – United States, Europe and Rest of World

REGIONAL MARKET OVERVIEW

THE UNITED STATES

Chart 32: United States Personalized Medicine Market Analysis (2008-2018) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million

Chart 33: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics

Chart 34: United States Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million

Chart 35: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

EUROPEChart 36: European Personalized Medicine Market Analysis (2008-2018) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD MillionChart 37: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other DiagnosticsChart 38: European Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD MillionChart 39: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

REST OF WORLD

Chart 40: Rest of World Personalized Medicine Market Analysis (2008-2018) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million

Chart 41: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics

Chart 42: Rest of World Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million

Chart 43: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

To order this report:In Vitro Diagnostic Industry: Personalized Medicine - A Global Market Overview

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. med fusion Partners with Theranostics Health to Advance Personalized Medicine for Patients with Cancer
2. University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients
3. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
4. AssureRx Health Launches Personalized Medicine Test for ADHD
5. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
6. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
7. Denmarks National Telemedicine Action Plan To Be Built On Continua Health Alliance Design Guidelines For Personal Connected Health Devices
8. NYU and NYU-Poly Launch Worlds First Academic Research Center to Combine Medicine with Wireless Communications and Computing
9. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
10. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
11. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology:
(Date:5/3/2016)... (PRWEB) , ... May 04, 2016 , ... ... for cancer. That message is reaching the global health community through expanding activities ... the burden of cancer in the resource-limited countries. , In support ...
(Date:5/3/2016)... ... May 03, 2016 , ... In April, Amerec launched a new website ... help find the best steam and sauna solutions. , First, the Amerec website has ... improvement brings all of the site’s features, especially the Steam Builder Tool , ...
(Date:5/3/2016)... ... May 03, 2016 , ... For over 23 years, ... providers to build the leading network of doctors and therapists treating personal injury patients ... of the distinguished Bay Chiropractic and Rehabilitation in Santa Monica, Doctors on ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Registration is now open for the 31st ... 5, 2016 at the Hatch Memorial Shell on the Esplanade. The event regularly draws thousands ... 5K Run is a competitive, timed event fully sanctioned by the USA Track & Field ...
(Date:5/3/2016)... Santa Monica, California (PRWEB) , ... May 03, 2016 , ... ... cosmetic surgery practice in late 2014, incorporating the injectable filler into his menu ... journeys of aesthetic transformation. Now, more than a year later, he’s still improving his ...
Breaking Medicine News(10 mins):